tooluniverse-pharmacovigilance

20
2
Source

Analyze drug safety signals from FDA adverse event reports, label warnings, and pharmacogenomic data. Calculates disproportionality measures (PRR, ROR), identifies serious adverse events, assesses pharmacogenomic risk variants. Use when asked about drug safety, adverse events, post-market surveillance, or risk-benefit assessment.

Install

mkdir -p .claude/skills/tooluniverse-pharmacovigilance && curl -L -o skill.zip "https://mcp.directory/api/skills/download/1769" && unzip -o skill.zip -d .claude/skills/tooluniverse-pharmacovigilance && rm skill.zip

Installs to .claude/skills/tooluniverse-pharmacovigilance

About this skill

Pharmacovigilance Safety Analyzer

Systematic drug safety analysis using FAERS adverse event data, FDA labeling, PharmGKB pharmacogenomics, and clinical trial safety signals.

KEY PRINCIPLES:

  1. Report-first approach - Create report file FIRST, update progressively
  2. Signal quantification - Use disproportionality measures (PRR, ROR)
  3. Severity stratification - Prioritize serious/fatal events
  4. Multi-source triangulation - FAERS, labels, trials, literature
  5. Pharmacogenomic context - Include genetic risk factors
  6. Actionable output - Risk-benefit summary with recommendations
  7. English-first queries - Always use English drug names and search terms in tool calls, even if the user writes in another language. Only try original-language terms as a fallback. Respond in the user's language

When to Use

Apply when user asks:

  • "What are the safety concerns for [drug]?"
  • "What adverse events are associated with [drug]?"
  • "Is [drug] safe? What are the risks?"
  • "Should I be concerned about [specific adverse event] with [drug]?"
  • "Compare safety profiles of [drug A] vs [drug B]"
  • "Pharmacovigilance analysis for [drug]"

Critical Workflow Requirements

1. Report-First Approach (MANDATORY)

  1. Create the report file FIRST:

    • File name: [DRUG]_safety_report.md
    • Initialize with all section headers
    • Add placeholder text: [Researching...]
  2. Progressively update as you gather data

  3. Output separate data files:

    • [DRUG]_adverse_events.csv - Ranked AEs with counts/signals
    • [DRUG]_pharmacogenomics.csv - PGx variants and recommendations

2. Citation Requirements (MANDATORY)

Every safety signal MUST include source:

### Signal: Hepatotoxicity
- **PRR**: 3.2 (95% CI: 2.8-3.7)
- **Cases**: 1,247 reports
- **Serious**: 892 (71.5%)
- **Fatal**: 23

*Source: FAERS via `FAERS_count_reactions_by_drug_event` (Q1 2020 - Q4 2025)*

Phase 0: Tool Verification

CRITICAL: Verify tool parameters before calling.

Known Parameter Corrections

ToolWRONG ParameterCORRECT Parameter
FAERS_count_reactions_by_drug_eventdrugdrug_name
DailyMed_search_splsnamedrug_name
PharmGKB_search_drugdrugquery
OpenFDA_get_drug_eventsdrug_namesearch

Workflow Overview

Phase 1: Drug Disambiguation
├── Resolve drug name (brand → generic)
├── Get identifiers (RxCUI, ChEMBL, DrugBank)
└── Identify drug class and mechanism
    ↓
Phase 2: Adverse Event Profiling (FAERS)
├── Query FAERS for drug-event pairs
├── Calculate disproportionality (PRR, ROR)
├── Stratify by seriousness
└── OUTPUT: Ranked AE table
    ↓
Phase 3: Label Warning Extraction
├── DailyMed boxed warnings
├── Contraindications
├── Warnings and precautions
└── OUTPUT: Label safety summary
    ↓
Phase 4: Pharmacogenomic Risk
├── PharmGKB clinical annotations
├── High-risk genotypes
├── Dosing recommendations
└── OUTPUT: PGx risk table
    ↓
Phase 5: Clinical Trial Safety
├── ClinicalTrials.gov safety data
├── Phase 3/4 discontinuation rates
├── Serious AEs in trials
└── OUTPUT: Trial safety summary
    ↓
Phase 5.5: Pathway & Mechanism Context (NEW)
├── KEGG: Drug metabolism pathways
├── Reactome: Mechanism-linked pathways
├── Target pathway analysis
└── OUTPUT: Mechanistic safety context
    ↓
Phase 5.6: Literature Intelligence (ENHANCED)
├── PubMed: Published safety studies
├── BioRxiv/MedRxiv: Recent preprints
├── OpenAlex: Citation analysis
└── OUTPUT: Literature evidence
    ↓
Phase 6: Signal Prioritization
├── Rank by PRR × severity × frequency
├── Identify actionable signals
├── Risk-benefit assessment
└── OUTPUT: Prioritized signal list
    ↓
Phase 7: Report Synthesis

Phase 1: Drug Disambiguation

1.1 Resolve Drug Identity

def resolve_drug(tu, drug_query):
    """Resolve drug name to standardized identifiers."""
    identifiers = {}
    
    # DailyMed for NDC and SPL
    dailymed = tu.tools.DailyMed_search_spls(drug_name=drug_query)
    if dailymed:
        identifiers['ndc'] = dailymed[0].get('ndc')
        identifiers['setid'] = dailymed[0].get('setid')
        identifiers['generic_name'] = dailymed[0].get('generic_name')
    
    # ChEMBL for molecule data
    chembl = tu.tools.ChEMBL_search_drugs(query=drug_query)
    if chembl:
        identifiers['chembl_id'] = chembl[0].get('molecule_chembl_id')
        identifiers['max_phase'] = chembl[0].get('max_phase')
    
    return identifiers

1.2 Output for Report

## 1. Drug Identification

| Property | Value |
|----------|-------|
| **Generic Name** | Metformin |
| **Brand Names** | Glucophage, Fortamet, Glumetza |
| **Drug Class** | Biguanide antidiabetic |
| **ChEMBL ID** | CHEMBL1431 |
| **Mechanism** | AMPK activator, hepatic gluconeogenesis inhibitor |
| **First Approved** | 1994 (US) |

*Source: DailyMed via `DailyMed_search_spls`, ChEMBL*

Phase 2: Adverse Event Profiling

2.1 FAERS Query Strategy

def get_faers_events(tu, drug_name, top_n=50):
    """Query FAERS for adverse events."""
    
    # Get event counts
    events = tu.tools.FAERS_count_reactions_by_drug_event(
        drug_name=drug_name,
        limit=top_n
    )
    
    # For each event, get detailed breakdown
    detailed_events = []
    for event in events:
        detail = tu.tools.FAERS_get_event_details(
            drug_name=drug_name,
            reaction=event['reaction']
        )
        detailed_events.append({
            'reaction': event['reaction'],
            'count': event['count'],
            'serious': detail.get('serious_count', 0),
            'fatal': detail.get('death_count', 0),
            'hospitalization': detail.get('hospitalization_count', 0)
        })
    
    return detailed_events

2.2 Disproportionality Analysis

Proportional Reporting Ratio (PRR):

PRR = (A/B) / (C/D)

Where:
A = Reports of drug X with event Y
B = Reports of drug X with any event
C = Reports of event Y with any drug (excluding X)
D = Total reports (excluding drug X)

Signal Thresholds:

MeasureSignal ThresholdStrong Signal
PRR>2.0>3.0
Chi-squared>4.0>10.0
N (case count)≥3≥10

2.3 Severity Classification

CategoryDefinitionPriority
FatalDeath outcomeHighest
Life-threateningImmediate death riskVery High
HospitalizationRequired/prolonged hospitalizationHigh
DisabilityPersistent impairmentHigh
Congenital anomalyBirth defectHigh
Other seriousMedical intervention requiredMedium
Non-seriousNo serious criteriaLow

2.4 Output for Report

## 2. Adverse Event Profile (FAERS)

**Data Period**: Q1 2020 - Q4 2025
**Total Reports for Drug**: 45,234

### 2.1 Top Adverse Events by Frequency

| Rank | Adverse Event | Reports | PRR | 95% CI | Serious (%) | Fatal |
|------|---------------|---------|-----|--------|-------------|-------|
| 1 | Diarrhea | 8,234 | 2.3 | 2.1-2.5 | 12% | 3 |
| 2 | Nausea | 6,892 | 1.8 | 1.6-2.0 | 8% | 0 |
| 3 | Lactic acidosis | 1,247 | 15.2 | 12.8-17.9 | 89% ⚠️ | 156 ⚠️ |
| 4 | Hypoglycemia | 2,341 | 2.1 | 1.9-2.4 | 34% | 8 |
| 5 | Vitamin B12 deficiency | 892 | 8.4 | 7.2-9.8 | 23% | 0 |

### 2.2 Serious Adverse Events Only

| Adverse Event | Serious Reports | Fatal | PRR | Signal |
|---------------|-----------------|-------|-----|--------|
| Lactic acidosis | 1,110 | 156 | 15.2 | **STRONG** ⚠️ |
| Acute kidney injury | 678 | 34 | 4.2 | Moderate |
| Hepatotoxicity | 234 | 12 | 3.1 | Moderate |

### 2.3 Signal Interpretation

**Strong Signal: Lactic Acidosis** ⚠️
- PRR of 15.2 indicates 15x higher reporting rate than expected
- 89% classified as serious
- 156 fatalities (12.5% case fatality)
- **Known class effect of biguanides**
- Risk factors: renal impairment, hypoxia, contrast agents

*Source: FAERS via `FAERS_count_reactions_by_drug_event`*

Phase 3: Label Warning Extraction

3.1 DailyMed Query

def extract_label_warnings(tu, setid):
    """Extract safety sections from FDA label."""
    
    label = tu.tools.DailyMed_get_spl_by_set_id(setid=setid)
    
    warnings = {
        'boxed_warning': label.get('boxed_warning'),
        'contraindications': label.get('contraindications'),
        'warnings_precautions': label.get('warnings_and_precautions'),
        'adverse_reactions': label.get('adverse_reactions'),
        'drug_interactions': label.get('drug_interactions')
    }
    
    return warnings

3.2 Warning Severity Categories

CategorySymbolDescription
Boxed WarningMost serious, life-threatening
Contraindication🔴Must not use
Warning🟠Significant risk
Precaution🟡Use caution

3.3 Output for Report

## 3. FDA Label Safety Information

### 3.1 Boxed Warning ⬛

**LACTIC ACIDOSIS**
> Metformin can cause lactic acidosis, a rare but serious complication. 
> Risk increases with renal impairment, sepsis, dehydration, excessive 
> alcohol intake, hepatic impairment, and acute heart failure.
> 
> **Contraindicated in patients with eGFR <30 mL/min/1.73m²**

### 3.2 Contraindications 🔴

| Contraindication | Rationale |
|------------------|-----------|
| eGFR <30 mL/min/1.73m² | Lactic acidosis risk |
| Acute/chronic metabolic acidosis | May worsen acidosis |
| Hypersensitivity to metformin | Allergic reaction |

### 3.3 Warnings and Precautions 🟠

| Warning | Clinical Action |
|---------|-----------------|
| Vitamin B12 deficiency | Monitor B12 levels annually |
| Hypoglycemia with insulin | Reduce insulin dose |
| Radiologic contrast | Hold 48h around procedure |
| Surgical procedures | Hold day of surgery

---

*Content truncated.*

tooluniverse-precision-oncology

mims-harvard

Provide actionable treatment recommendations for cancer patients based on molecular profile. Interprets tumor mutations, identifies FDA-approved therapies, finds resistance mechanisms, matches clinical trials. Use when oncologist asks about treatment options for specific mutations (EGFR, KRAS, BRAF, etc.), therapy resistance, or clinical trial eligibility.

203

tooluniverse-drug-research

mims-harvard

Generates comprehensive drug research reports with compound disambiguation, evidence grading, and mandatory completeness sections. Covers identity, chemistry, pharmacology, targets, clinical trials, safety, pharmacogenomics, and ADMET properties. Use when users ask about drugs, medications, therapeutics, or need drug profiling, safety assessment, or clinical development research.

213

drug-repurposing

mims-harvard

Identify drug repurposing candidates using ToolUniverse for target-based, compound-based, and disease-driven strategies. Searches existing drugs for new therapeutic indications by analyzing targets, bioactivity, safety profiles, and literature evidence. Use when exploring drug repurposing opportunities, finding new indications for approved drugs, or when users mention drug repositioning, off-label uses, or therapeutic alternatives.

202

tooluniverse-expression-data-retrieval

mims-harvard

Retrieves gene expression and omics datasets from ArrayExpress and BioStudies with gene disambiguation, experiment quality assessment, and structured reports. Creates comprehensive dataset profiles with metadata, sample information, and download links. Use when users need expression data, omics datasets, or mention ArrayExpress (E-MTAB, E-GEOD) or BioStudies (S-BSST) accessions.

172

tooluniverse-target-research

mims-harvard

Gather comprehensive biological target intelligence from 9 parallel research paths covering protein info, structure, interactions, pathways, expression, variants, drug interactions, and literature. Features collision-aware searches, evidence grading (T1-T4), explicit Open Targets coverage, and mandatory completeness auditing. Use when users ask about drug targets, proteins, genes, or need target validation, druggability assessment, or comprehensive target profiling.

52

tooluniverse-literature-deep-research

mims-harvard

Conduct comprehensive literature research with target disambiguation, evidence grading, and structured theme extraction. Creates a detailed report with mandatory completeness checklist, biological model synthesis, and testable hypotheses. For biological targets, resolves official IDs (Ensembl/UniProt), synonyms, naming collisions, and gathers expression/pathway context before literature search. Default deliverable is a report file; for single factoid questions, uses a fast verification mode and may include an inline answer. Use when users need thorough literature reviews, target profiles, or to verify specific claims from the literature.

122

You might also like

flutter-development

aj-geddes

Build beautiful cross-platform mobile apps with Flutter and Dart. Covers widgets, state management with Provider/BLoC, navigation, API integration, and material design.

1,5721,370

ui-ux-pro-max

nextlevelbuilder

"UI/UX design intelligence. 50 styles, 21 palettes, 50 font pairings, 20 charts, 8 stacks (React, Next.js, Vue, Svelte, SwiftUI, React Native, Flutter, Tailwind). Actions: plan, build, create, design, implement, review, fix, improve, optimize, enhance, refactor, check UI/UX code. Projects: website, landing page, dashboard, admin panel, e-commerce, SaaS, portfolio, blog, mobile app, .html, .tsx, .vue, .svelte. Elements: button, modal, navbar, sidebar, card, table, form, chart. Styles: glassmorphism, claymorphism, minimalism, brutalism, neumorphism, bento grid, dark mode, responsive, skeuomorphism, flat design. Topics: color palette, accessibility, animation, layout, typography, font pairing, spacing, hover, shadow, gradient."

1,1161,191

drawio-diagrams-enhanced

jgtolentino

Create professional draw.io (diagrams.net) diagrams in XML format (.drawio files) with integrated PMP/PMBOK methodologies, extensive visual asset libraries, and industry-standard professional templates. Use this skill when users ask to create flowcharts, swimlane diagrams, cross-functional flowcharts, org charts, network diagrams, UML diagrams, BPMN, project management diagrams (WBS, Gantt, PERT, RACI), risk matrices, stakeholder maps, or any other visual diagram in draw.io format. This skill includes access to custom shape libraries for icons, clipart, and professional symbols.

1,4181,109

godot

bfollington

This skill should be used when working on Godot Engine projects. It provides specialized knowledge of Godot's file formats (.gd, .tscn, .tres), architecture patterns (component-based, signal-driven, resource-based), common pitfalls, validation tools, code templates, and CLI workflows. The `godot` command is available for running the game, validating scripts, importing resources, and exporting builds. Use this skill for tasks involving Godot game development, debugging scene/resource files, implementing game systems, or creating new Godot components.

1,194747

nano-banana-pro

garg-aayush

Generate and edit images using Google's Nano Banana Pro (Gemini 3 Pro Image) API. Use when the user asks to generate, create, edit, modify, change, alter, or update images. Also use when user references an existing image file and asks to modify it in any way (e.g., "modify this image", "change the background", "replace X with Y"). Supports both text-to-image generation and image-to-image editing with configurable resolution (1K default, 2K, or 4K for high resolution). DO NOT read the image file first - use this skill directly with the --input-image parameter.

1,154684

pdf-to-markdown

aliceisjustplaying

Convert entire PDF documents to clean, structured Markdown for full context loading. Use this skill when the user wants to extract ALL text from a PDF into context (not grep/search), when discussing or analyzing PDF content in full, when the user mentions "load the whole PDF", "bring the PDF into context", "read the entire PDF", or when partial extraction/grepping would miss important context. This is the preferred method for PDF text extraction over page-by-page or grep approaches.

1,313614

Stay ahead of the MCP ecosystem

Get weekly updates on new skills and servers.